Minerva Neurosciences, Inc. Retained Earnings
Minerva Neurosciences, Inc. (NERV) had Retained Earnings of -$796.74 million as of 2026-06-30, per its 10-Q filed 2026-08-07.
Financial Statements › Balance Sheet › Equity › Equity, Attributable to Parent
us-gaap:RetainedEarningsAccumulatedDeficit · last filed 2026-08-07
- 2026-06-30: Retained Earnings (Accumulated Deficit) -$796.74M.
- 2026-03-31: Retained Earnings (Accumulated Deficit) -$814.20M.
- 2025-12-31: Retained Earnings (Accumulated Deficit) -$688.80M.
- 2025-09-30: Retained Earnings (Accumulated Deficit) -$405.13M.
| Period end | Retained Earnings (Accumulated Deficit) | Retained Earnings (Accumulated Deficit) as first filed |
|---|---|---|
| 2026-06-30 | -$796.74M 10-Q · filed 2026-08-07 | |
| 2026-03-31 | -$814.20M 10-Q · filed 2026-05-05 | |
| 2025-12-31 | -$688.80M 10-Q · filed 2026-08-07 | |
| 2025-09-30 | -$405.13M 10-Q · filed 2025-11-05 | |
| 2025-06-30 | -$402.39M 10-Q · filed 2025-08-14 | |
| 2025-03-31 | -$399.13M 10-Q · filed 2025-05-13 | |
| 2024-12-31 | -$395.38M 10-K · filed 2026-03-11 | |
| 2024-09-30 | -$391.10M 10-Q · filed 2024-11-05 | |
| 2024-06-30 | -$413.62M 10-Q · filed 2024-08-06 | |
| 2024-03-31 | -$405.38M 10-Q · filed 2024-05-01 | |
| 2023-12-31 | -$396.82M 10-K · filed 2025-02-25 | |
| 2023-09-30 | -$387.79M 10-Q · filed 2023-11-07 | |
| 2023-06-30 | -$379.97M 10-Q · filed 2023-08-01 | |
| 2023-03-31 | -$373.78M 10-Q · filed 2023-05-15 | |
| 2022-12-31 | -$366.81M 10-K · filed 2024-02-22 | |
| 2022-09-30 | -$360.08M 10-Q · filed 2022-11-09 | |
| 2022-06-30 | -$353.18M 10-Q · filed 2022-08-09 | |
| 2022-03-31 | -$344.47M 10-Q · filed 2022-05-04 | |
| 2021-12-31 | -$334.70M 10-K · filed 2023-03-08 | |
| 2021-09-30 | -$313.39M 10-Q · filed 2021-11-08 | |
| 2021-06-30 | -$304.19M 10-Q · filed 2021-08-02 | |
| 2021-03-31 | -$344.50M 10-Q · filed 2022-05-04 | -$293.60M 10-Q · filed 2021-05-12 |
| 2020-12-31 | -$284.80M 10-K · filed 2022-03-01 | |
| 2020-09-30 | -$277.47M 10-Q · filed 2020-11-02 | |
| 2020-06-30 | -$304.20M 10-Q · filed 2021-08-02 | -$269.36M 10-Q · filed 2020-08-03 |
| 2020-03-31 | -$298.89M 10-Q · filed 2020-05-04 | |
| 2019-12-31 | -$286.74M 10-K · filed 2021-03-08 | |
| 2019-09-30 | -$256.82M 10-Q · filed 2019-11-04 | |
| 2019-06-30 | -$242.86M 10-Q · filed 2019-08-05 | |
| 2019-03-31 | -$230.38M 10-Q · filed 2019-05-06 | |
| 2018-12-31 | -$214.55M 10-K · filed 2020-03-09 | |
| 2018-09-30 | -$201.35M 10-Q · filed 2018-11-05 | |
| 2018-06-30 | -$189.33M 10-Q · filed 2018-08-02 | |
| 2018-03-31 | -$176.80M 10-Q · filed 2018-05-03 | |
| 2017-12-31 | -$164.38M 10-K · filed 2019-03-12 | |
| 2017-09-30 | -$164.54M 10-Q · filed 2017-11-06 | |
| 2017-06-30 | -$153.28M 10-Q · filed 2017-08-03 | |
| 2017-03-31 | -$143.50M 10-Q · filed 2017-05-04 | |
| 2016-12-31 | -$132.86M 10-K · filed 2018-03-12 | |
| 2016-09-30 | -$123.45M 10-Q · filed 2016-11-03 | |
| 2016-06-30 | -$115.03M 10-Q · filed 2016-08-04 | |
| 2016-03-31 | -$109.82M 10-Q · filed 2016-05-03 | |
| 2015-12-31 | -$101.81M 10-K · filed 2017-03-13 | |
| 2015-09-30 | -$93.37M 10-Q · filed 2015-11-05 | |
| 2015-06-30 | -$87.43M 10-Q · filed 2015-08-05 | |
| 2015-03-31 | -$80.82M 10-Q · filed 2015-05-07 | |
| 2014-12-31 | -$74.73M 10-K · filed 2016-03-14 | |
| 2014-09-30 | -$67.29M 10-Q · filed 2014-11-06 | |
| 2014-06-30 | -$40.13M 10-Q · filed 2014-08-07 | |
| 2013-12-31 | -$17.83M 10-K · filed 2015-03-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Tonix Pharmaceuticals Holding Corp. (TNXP) | United States | $0.166B | -1.34 |
| ADC Therapeutics SA (ADCT) | $0.163B | -1.39 | |
| LIFECORE BIOMEDICAL, INC. DE (LFCR) | United States | $0.163B | -8.50 |
| Organogenesis Holdings Inc. (ORGO) | United States | $0.182B | -3.70 |
| Annexon, Inc. (ANNX) | United States | $0.147B | -4.22 |
| AN2 Therapeutics, Inc. (ANTX) | United States | $0.185B | -4.84 |
| PepGen Inc. (PEPG) | United States | $0.186B | -1.73 |
| Corbus Pharmaceuticals Holdings, Inc. (CRBP) | United States | $0.144B | -1.72 |
| ALX ONCOLOGY HOLDINGS INC (ALXO) | United States | $0.187B | -3.52 |
| Fortress Biotech, Inc. (FBIO) | United States | $0.188B | 0.91 |